In prostate cancer, PIM1 has been shown to play a role in metastases through a number of pathways, including (i) the activation of NFATC1, c-Myc, and Smad signaling, (ii) the inhibition of GSK3β and FOXP3, (iii) the upregulation of PTGS2, and (iv) altering integrin-dependent cell adhesion [75,77,78,79]. The gene discussed is PIM1; the disease is prostate carcinoma.